|Videos|May 2, 2022
Safety and Efficacy Data: The KEYNOTE-426 Trial
Arnab Basu, MD, MPH, FACP discusses data from the KEYNOTE-426 trial of axitinib/pembrolizumab versus sunitinib in metastatic RCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5